Cullinan Oncology Statistics
Share Statistics
Cullinan Oncology has 58.23M shares outstanding. The number of shares has increased by 35.52% in one year.
| Shares Outstanding | 58.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.59% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 37.15M |
| Failed to Deliver (FTD) Shares | 152 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 9.02M, so 15.49% of the outstanding shares have been sold short.
| Short Interest | 9.02M |
| Short % of Shares Out | 15.49% |
| Short % of Float | 24.34% |
| Short Ratio (days to cover) | 24.87 |
Valuation Ratios
The PE ratio is -2.76 and the forward PE ratio is -4.93.
| PE Ratio | -2.76 |
| Forward PE | -4.93 |
| PS Ratio | 0 |
| Forward PS | 91.9 |
| PB Ratio | 0.93 |
| P/FCF Ratio | -3.15 |
| PEG Ratio | n/a |
Enterprise Valuation
Cullinan Oncology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 17.07, with a Debt / Equity ratio of 0.
| Current Ratio | 17.07 |
| Quick Ratio | 17.07 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.32 |
| Cash Flow / Debt | -93.25 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -38.28%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -38.28% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.80M |
| Employee Count | 85 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -14.12M |
| Effective Tax Rate | 0.08 |
Stock Price Statistics
The stock price has increased by 42.84% in the last 52 weeks. The beta is -0.12, so Cullinan Oncology 's price volatility has been lower than the market average.
| Beta | -0.12 |
| 52-Week Price Change | 42.84% |
| 50-Day Moving Average | 14.9 |
| 200-Day Moving Average | 18.05 |
| Relative Strength Index (RSI) | 35.69 |
| Average Volume (20 Days) | 541.91K |
Income Statement
In the last 12 months, Cullinan Oncology had revenue of $0 and earned -$153.16M in profits. Earnings per share was $-3.69.
| Revenue | 0 |
| Gross Profit | -310.00K |
| Operating Income | -191.09M |
| Net Income | -153.16M |
| EBITDA | -190.34M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.69 |
Balance Sheet
The company has $98.43M in cash and $3.59M in debt, giving a net cash position of $94.84M.
| Cash & Cash Equivalents | 98.43M |
| Total Debt | 3.59M |
| Net Cash | 94.84M |
| Retained Earnings | -200.86M |
| Total Assets | 653.25M |
| Working Capital | 567.84M |
Cash Flow
In the last 12 months, operating cash flow was -$134.28M and capital expenditures -$208.00K, giving a free cash flow of -$134.48M.
| Operating Cash Flow | -134.28M |
| Capital Expenditures | -208.00K |
| Free Cash Flow | -134.48M |
| FCF Per Share | -3.24 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CGEM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -31.35% |
| FCF Yield | -19.62% |
Analyst Forecast
The average price target for CGEM is $29.5, which is 150.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.5 |
| Price Target Difference | 150.6% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 16.2 |
| Piotroski F-Score | 2 |